Jefferies Group LLC reissued their hold rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a report issued on Wednesday. They currently have a $126.00 price objective on the biotechnology company’s stock.
A number of other analysts have also weighed in on BLUE. Morgan Stanley reiterated an equal weight rating and issued a $105.00 target price (up previously from $91.00) on shares of bluebird bio in a research note on Wednesday, June 14th. Standpoint Research reiterated a reduce rating and issued a $110.00 target price on shares of bluebird bio in a research note on Friday, June 16th. BidaskClub upgraded bluebird bio from a buy rating to a strong-buy rating in a research note on Friday, June 23rd. Wedbush reiterated an outperform rating and issued a $100.00 target price (down previously from $121.00) on shares of bluebird bio in a research note on Friday, June 23rd. Finally, Cowen and Company reiterated a buy rating on shares of bluebird bio in a research note on Friday, June 23rd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $118.81.
bluebird bio (NASDAQ:BLUE) traded up 3.87% during mid-day trading on Wednesday, reaching $130.31. 704,297 shares of the company traded hands. The company’s 50 day moving average price is $124.56 and its 200 day moving average price is $101.78. bluebird bio has a 12-month low of $37.05 and a 12-month high of $143.50. The firm’s market capitalization is $5.94 billion.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. During the same quarter in the previous year, the business earned ($1.59) EPS. The business’s revenue for the quarter was up 977.4% on a year-over-year basis. Equities research analysts predict that bluebird bio will post ($6.79) EPS for the current year.
In related news, Director Daniel Lynch sold 500 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $120.00, for a total transaction of $60,000.00. Following the sale, the director now owns 3,300 shares of the company’s stock, valued at $396,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric Sullivan sold 861 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total value of $80,787.63. Following the sale, the insider now directly owns 5,924 shares in the company, valued at approximately $555,848.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 131,779 shares of company stock worth $16,038,514. 3.90% of the stock is owned by corporate insiders.
A number of hedge funds have recently modified their holdings of BLUE. QS Investors LLC boosted its position in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares in the last quarter. Bank of Montreal Can boosted its position in bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares in the last quarter. Turner Investments LLC bought a new stake in bluebird bio during the second quarter valued at about $184,000. SG Americas Securities LLC boosted its position in bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. bought a new stake in bluebird bio during the second quarter valued at about $210,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.